Table II.
Demographic and clinical characteristics of compound betamethasone–treated patients according to response to treatment
| Variable | No response (n = 9) | Relapse (n = 40) | Remission (n = 10) | P value |
|---|---|---|---|---|
| Age, y | 45 ± 21 | 45 ± 15 | 47 ± 11 | .93 |
| Women, No. (%) | 6 (66.7) | 21 (52.5) | 7 (70.0) | .53 |
| Duration of disease, mo | 22 ± 17 | 19 ± 23 | 25 ± 35 | .78 |
| Total follow-up, mo | 30 ± 25 | 40 ± 28 | 28 ± 22 | .35 |
| Odontogenic infection, No. (%) | 6 (66.7) | 20 (50.0) | 3 (30.0) | .30 |
| Lip enlargement, No. (%) | .65 | |||
| Upper | 2 (22.2) | 11 (27.5) | 3 (30.0) | |
| Lower | 5 (55.6) | 12 (30.0) | 4 (40.0) | |
| Both | 2 (22.2) | 17 (42.5) | 3 (30.0) | |
| Extent of disease, No. (%) | .39 | |||
| Solely lip manifestation | 3 (33.3) | 17 (42.5) | 6 (60.0) | |
| Intraoral manifestation | 5 (55.6) | 16 (40.0) | 2 (20.0) | |
| Perioral or facial swelling, erythema | 1 (11.1) | 7 (17.5) | 2 (20.0) |
Data are expressed as mean ± standard deviation. Remission group included partial remission and complete remission cases.